Clinical Trials
2 trialsNCT06953960 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed